Loading…
Makes automated medication dispensing cabinets and pharmacy workflow software used by hospitals and pharmacies.
Makes automated medication dispensing cabinets and pharmacy workflow software used by hospitals and pharmacies.
Sells cabinets and robotic dispensing systems to hospitals and pharmacies, then earns recurring revenue from software subscriptions and service contracts on the installed base, a mix it has been trying to grow.
Moat: narrow (installed base, switching costs, regulatory licence). Hardware/software embedded in hospital medication workflows is costly and risky for hospitals to replace.
Headquarters: Cranberry Township, Pennsylvania, United States · Founded: 1992 · Employees: 3,580
Size Omnicell (OMCL) is a United States Information Technology company (Information Technology Services) with a market value of $1.70B, the 1900th largest of 3,117 United States companies the cockpit tracks. Shares closed at $37.34 on 6 Nov 2026.
Performance Over six months the shares fell 14.8%, against -12.5% for the median peer and -1.1% for the United States market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 5.6% over the last twelve months (peer median +7.9%); the operating margin is 5.3% (peer median 7.8%).
Valuation It trades at 19.5× forward earnings against a peer median of 31.1× (5th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.5 points below its cost of capital (8.9% WACC).
Backlog Backlog (remaining performance obligations) was $375M at 30 Sep 2026, down 1% on a year earlier — 0.3 years of trailing revenue. Backlog detail →
Credit Omnicell has 1 bond outstanding ($172M).
Short interest Short interest is 7.2% of the free float (15 Oct 2026).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.24B | $1.18B | $1.11B | $1.15B | $1.30B |
| Revenue growth | — | +7% | -3% | -11% | — |
| Gross profit | $561M | $508M | $476M | $500M | $597M |
| EBITDA | $155M | $98.3M | $95.2M | $76.2M | $120M |
| Net income | $44.7M | $2.05M | $12.5M | -$20.4M | $5.65M |
| Free cash flow | $143M | $84.5M | $151M | $140M | $30.2M |
| Capital expenditure | $55.9M | $60.4M | $52.8M | $55.0M | $60.7M |
| Total debt | $190M | $204M | $383M | $614M | $617M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Omnicell OMCL | $1.70B | -15% | +6% | 5% | 19.5× | 11.7% |
| Becton Dickinson BDX | $57.7B | +43% | -3% | 15% | 16.0× | 9.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | OMCL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.2% | -2.7% | 5th highest of 21 |
| 6-month return | -14.8% | -12.5% | 9th lowest of 21 |
| Distance from 52-week high | -32.1% | -34.0% | 10th highest of 21 |
| Revenue growth (TTM) | +5.6% | +7.9% | 10th lowest of 21 |
| Operating margin | 5.3% | 7.8% | 7th lowest of 21 |
| Forward P/E | 19.5× | 31.1× | 5th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 11.7% | 16.2% | 4th least demanding of 10 |
| Growth delivered (Del g) | +5.8% | +15.8% | 4th lowest of 10 |
| Hurdle (Req g minus delivered) | +5.8 pp | -3.9 pp | 4th most demanding of 10 |
| ROIC minus cost of capital | -4.5 pp | -2.7 pp | 8th lowest of 19 |
| EV / EBITDA | 10.0× | 24.0× | 2nd cheapest of 10 |
| Net debt / EBITDA | -0.9× | 0.2× | 5th least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Omnicell OMCL | United States | $1.70B | -15% | +6% | 5% | 19.5× | 11.7% | +5.8% |
| Shift 3697.T | Japan | $1.71B | +61% | +24% | 11% | 19.2× | -2.2% | +28.6% |
| Transportation Telecommunication and Information Development Inc. Ltd. Zhejiang 300469.SZ | China | $1.72B | -18% | -15% | -102% | n/a | n/a | n/a |
| Northking Information Technology 002987.SZ | China | $1.67B | -14% | +1% | 6% | 30.6× | 16.2% | +16.1% |
| Simplex Holdings,Inc 4373.T | Japan | $1.66B | +25% | +20% | 23% | 19.4× | 12.4% | +16.3% |
| secunet Security Networks YSN.DE | Germany | $1.66B | +20% | +13% | 11% | 37.3× | n/a | n/a |
| Formula Systems (1985) Ltd. Sponsored ADR FORTY | United States | $1.75B | -26% | +1% | 8% | n/a | -3.4% | +6.3% |
| Mega Fortune MGRT | United States | $1.65B | -14% | -8% | -37% | n/a | n/a | n/a |
| Zen Technologies ZENTEC.NS | India | $1.64B | +6% | +4% | 31% | 45.7× | 53.0% | +66.0% |
| CETC Cyberspace Security Technology 002268.SZ | China | $1.77B | -11% | -3% | 1% | 45.0× | n/a | n/a |
| CETC Digital Technology 600850.SS | China | $1.62B | -18% | -1% | 2% | 17.3× | 19.1% | +5.8% |
| A10 Networks ATEN | United States | $1.80B | -11% | +12% | 17% | 22.0× | 16.7% | +5.2% |
| PDF Solutions PDFS | United States | $1.59B | -27% | +23% | 8% | 26.0× | n/a | n/a |
| Sigma Advanced Systems SIGMAADV.NS | India | $1.83B | +196% | +358% | 12% | n/a | n/a | n/a |
| Concentrix CNXC | United States | $1.85B | +25% | +3% | 8% | 2.6× | -11.9% | +15.8% |
| Computer Age Management Services CAMS.NS | India | $1.87B | -15% | +9% | 39% | 32.3× | n/a | n/a |
| Data#3 DTL.AX | Australia | $1.54B | +81% | +6% | 8% | 31.6× | 26.9% | -14.2% |
| Shenzhen YSSTech Information Technology 300377.SZ | China | $1.53B | -24% | +14% | -3% | n/a | n/a | n/a |
| Black Box BBOX.NS | India | $1.53B | +10% | +12% | 7% | 47.3× | n/a | n/a |
| Shenzhen Forms Syntron Information 300468.SZ | China | $1.52B | -33% | +9% | 9% | n/a | n/a | n/a |
| Cetc Potevio Science & Technology 002544.SZ | China | $1.52B | -41% | 0% | 0% | 375.0× | n/a | n/a |
Omnicell has 1 bond outstanding with $172M face value.
Omnicell reported $375M of remaining performance obligations at 30 Sep 2026, down 1% from a year earlier and flat from the previous quarter. That is 0.3 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.